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Abstract
Background: The occurrence of tuberculosis (TB), human immunodeficiency virus (HIV), and viral hepatitis infections in the
same patient poses unique clinical and public health challenges, because medications to treat TB and HIV are hepatotoxic. We
conducted an observational study to evaluate risk factors for HBsAg and/or anti-HCV reactivity and to assess differences in
adverse events and TB treatment outcomes among HIV-infected TB patients.
Methods: Patients were evaluated at the beginning, during, and at the end of TB treatment. Blood samples were tested for
aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (BR), complete blood count, and CD4+ T
lymphocyte cell count. TB treatment outcomes were assessed at the end of TB treatment according to international guidelines.
Results: Of 769 enrolled patients, 752 (98%) had serologic testing performed for viral hepatitis: 70 (9%) were reactive for
HBsAg, 237 (31%) for anti-HCV, and 472 (63%) non-reactive for both markers. At the beginning of TB treatment, 18 (26%)
patients with HBsAg reactivity had elevated liver function tests compared with 69 (15%) patients non-reactive to any viral
marker (p = 0.02). At the end of TB treatment, 493 (64%) were successfully treated. Factors independently associated with
HBsAg reactivity included being a man who had sex with men (adjusted odds ratio [AOR], 2.1; 95% confidence interval [CI],
1.1–4.3) and having low TB knowledge (AOR, 1.8; CI, 1.0–3.0). Factors most strongly associated with anti-HCV reactivity were
having injection drug use history (AOR, 12.8; CI, 7.0–23.2) and living in Bangkok (AOR, 15.8; CI, 9.4–26.5). The rate of clinical
hepatitis and death during TB treatment was similar in patients HBsAg reactive, anti-HCV reactive, both HBsAg and anti-HCV
reactive, and non-reactive to any viral marker.
Conclusion: Among HIV-infected TB patients living in Thailand, markers of viral hepatitis infection, particularly hepatitis C virus
infection, were common and strongly associated with known behavioral risk factors. Viral hepatitis infection markers were not
strongly associated with death or the development of clinical hepatitis during TB treatment.
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Background
Over nine million new cases of tuberculosis (TB) occur
annually throughout the world. While most of these cases
can safely and effectively be treated, complications can
occur during TB treatment, because of anti-TB drug resist-
ance, poor adherence, drug-drug interactions, and toxic-
ity.[1] Liver toxicity is a particularly common side effect
that is strongly associated with three of the four anti-TB
drugs included in the most widely accepted regimen.[2,3]
The burden of TB continues to rise in some regions of the
world, because of the human immunodeficiency virus
(HIV) epidemic. This TB/HIV syndemic has also increased
the clinical complexity of managing patients. Medications
used to prevent opportunistic infections or treat HIV are
often hepatotoxic, and opportunistic infections may
involve the liver. [4-6]
The epidemics of hepatitis B and/or C virus infection
(HBV and HCV, respectively) involve many of the popu-
lations that are at risk of HIV infection. This is particularly
true in Eastern Europe and Asia, where injection drug use
is a potent driver of the HIV epidemic. [7-9] The occur-
rence of TB, HIV, and viral hepatitis infection in the same
patient poses unique challenges to clinicians and public
health officials. A major concern is that such patients may
acquire clinical hepatitis during treatment with the first-
line TB or HIV regimens available in most of the world.
One study in HIV-infected TB patients demonstrated a
doubling in liver enzyme levels in 14% of patients with
HBV and 12% of patients with HCV infection, although
few had symptomatic hepatitis.[10] Another small study
found that 5 of 11 (45%) patients with both HCV and HIV
infection developed drug-induced hepatitis during TB
treatment; the risk of hepatitis was over 3 times greater
than in those with HIV infection alone and over 14 times
greater than in those with neither HIV nor HCV infec-
tion.[11]
Thailand is one of 22 World Health Organization
(WHO)-designated "high burden" TB countries and has a
generalized HIV epidemic.[12,13] Over 15% of TB
patients in Thailand have HIV infection.[14] Among
blood donors born before the introduction of universal
hepatitis B vaccination in 1992, the percentage of Thais
with hepatitis B surface antigen (HBsAg) and antibodies
to HCV (anti-HCV) ranged from 4% to 13%[15] and 1%
to 4% [15-17], respectively. Little is known about the bur-
den of HBV and HCV infection in HIV-infected TB
patients, or the impact of these infections on TB treatment
outcomes in Thailand. We conducted an observational
study in four provinces in Thailand to evaluate the preva-
lence of and risk factors for HBsAg and/or anti-HCV reac-
tivity among HIV-infected TB patients undergoing TB
treatment. We also evaluated the impact of HBV and HCV
infections on adverse events during TB treatment and on
final TB treatment outcome.
Methods
Study setting and population
We conducted a multi-center, observational, prospective
cohort study among HIV-infected TB patients at public TB
treatment facilities in Bangkok, Phuket, and Ubon Rat-
chathani provinces and at the national infectious diseases
disease referral hospital (Bamrasnaradura Infectious Dis-
eases Institute) in Nonthaburi province from May 2005 to
September 2006. The study population included adults
aged ≥ 18 years with documented HIV infection who were
diagnosed with active TB disease according to national TB
program guidelines[18], registered for TB treatment at one
of the participating facilities, and received anti-TB therapy
(for this episode of TB) for <4 weeks before study enroll-
ment. We excluded prisoners and pregnant women.
Patients with previous history of TB treatment were eligi-
ble for the study. Patients providing written informed
consent were followed from TB treatment initiation to the
end of TB treatment. For this study, patients received usual
care for TB, HIV, and other diseases, and no health-related
interventions were performed. In Thailand, patients with
no prior history of TB treatment usually receive isoniazid,
rifampin, ethambutol, and pyrazinamide. When pre-
scribed anti-retroviral therapy, HIV-infected patients usu-
ally receive stavudine, lamivudine, and nevirapine; in
patients with TB, efavirenz is recommended as a substitute
for nevirapine.
Data collection and laboratory studies
Patients had three study visits during TB treatment: at the
beginning of treatment, at the end of the intensive phase
of TB treatment (usually two months into treatment), and
at the end of TB treatment (usually six months after treat-
ment initiation). At the beginning of treatment, patients
were interviewed using standardized study forms that
asked about demographic characteristics, past and present
medical history, knowledge and attitudes related to TB
and HIV, and sex and drug use history. At every study visit,
patients received a physical examination and were asked
about medications taken and any adverse events experi-
enced since their previous visit. Medical records were
reviewed for results of examinations or tests performed
between study visits. Adverse events were defined as any
health-related problem that occurred during study follow-
up, that was plausibly related to TB or HIV treatment, and
that necessitated a physician evaluation. For adverse
events, a definition of "liver disease" was applied to any
patient who was diagnosed by a physician has having hep-
atitis, jaundice, or cirrhosis.
At the beginning of treatment, blood samples were tested
for HBsAg and anti-HCV. No other tests of viral hepatitisBMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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infection were performed. These serologic tests for viral
hepatitis markers were performed at the health facility
enrolling the patient or, if necessary, at a centralized gov-
ernment laboratory in each respective province. For
HBsAg, the following assays were used: Enzygnost (Dade
Behring, Germany); AxSym HBsAg, version 2 (Abbott,
Abbott Park, USA). For anti-HCV, the following assays
were used: anti-HCV ELISA (Abbott, Abbott Park, USA);
AxSym, version 3.0 (Abbott, Abbott Park, USA); HCV Tri-
Dot (J. Mitra, India). In addition, blood samples were
tested for aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), total bilirubin (BR), complete blood
count, and CD4+ T lymphocyte (CD4) cell count at the
beginning of treatment. In these laboratories, the upper
limit of normal for AST was 35 units/L, ALT 33 units/L,
and total bilirubin 1 mg/dL. Sputum and specimens from
extra-pulmonary sites were collected for acid fast bacilli
(AFB) smear, mycobacterial culture, identification, and
drug-susceptibility testing.
TB treatment outcomes were assessed at the end of TB
treatment according to the national TB program and
WHO guidelines; successful TB treatment comprised both
cure and completed treatment.[18] For patients recorded
as defaulting during TB treatment, we reviewed govern-
ment vital registration data to determine whether patients
died within 90 days of stopping TB treatment; such
patients were re-classified as deaths during TB treatment.
Statistical analysis
We calculated a TB knowledge score as the sum of correct
answers to seven questions about TB and TB treatment;
these questions were derived from information routinely
provided to patients as part of the national TB program.
High TB knowledge was defined as having a TB knowledge
score equal to or greater than the median score of the
study population. Similarly, we calculated a TB stigma
score as the sum of four questions about TB stigma that a
patient answered affirmatively (e.g., "Would you share a
meal with someone with TB?"). Low TB stigma was
defined as having a TB stigma score less than the median
score of the study population.
We calculated proportions to describe demographic char-
acteristics, clinical features, and adverse events. We ana-
lyzed groups stratified by viral hepatitis marker (HBsAg,
anti-HCV, and both HBsAg and anti-HCV). However,
patients were not broken down into 3 mutually exclusive
categories: a patient who was positive for both markers
was in the HBsAg analysis, the HCV analysis, and the
"both" HBsAg and anti-HCV analysis. To identify charac-
teristics predictive of these viral hepatitis markers, we first
identified factors associated with each marker at p = 0.20
in univariate analysis and then constructed multivariate
logistic regression models. For each multivariate analysis,
we fitted a full model and a parsimonious model using a
backward stepwise variable selection procedure. Findings
from both models were similar; therefore, we reported
estimates from the full model. There were 732, 736, and
740 patients included in the HBsAg, anti-HCV, and both
HBsAg and anti-HCV analyses, respectively.
To determine whether different viral hepatitis markers
were associated with different TB treatment outcomes, we
analyzed the likelihood of death or a composite end point
of death and default vs. TB treatment success, adjusted for
factors associated with TB treatment outcome at p = 0.20
in univariate analysis. We fitted full and parsimonious
models. Findings from both models were similar; we
reported the estimates from the former. A subset of
patients with culture-confirmed TB (defined as having any
specimen culture-positive for MTB) was also analyzed.
For analysis of risk factors for viral hepatitis or the out-
comes of TB treatment, we excluded 17 patients with una-
vailable viral hepatitis serology test results. In all analyses,
we defined a two-sided p-value of ≤ 0.05 as statistical sig-
nificance. We performed all analyses using Stata software
version 8.0 (StataCorp LP, College Station, TX, U.S.A.).
Ethical review
This study was approved by the ethical review committees
of the Bangkok Metropolitan Administration, the Thai-
land Ministry of Public Health, and the U.S. Centers for
Disease Control and Prevention.
Results
Characteristics and clinical features
We enrolled 849 HIV-infected TB patients in the study.
Excluding those whose diagnosis of TB was subsequently
changed (e.g., cultures grew non-tuberculosis mycobacte-
ria), 769 (91%) were retained in the analysis (Figure 1).
Of these, 752 (98%) had serologic tests for viral hepatitis
infection. Seventy (9%) patients were reactive for HBsAg,
237 (31%) for anti-HCV, and 472 (63%) non-reactive for
both HBsAg and anti-HCV. Twenty-seven (4%) patients
were reactive for both HBsAg and anti-HCV. The median
age of patients was 34 (interquartile range [IQR], 30–41)
years, and most patients were male and employed (Table
1). Of the 769 patients, 461 (60%) had pulmonary TB,
and 667 (87%) had not previously been treated for TB.
The median AST among patients reactive to HBsAg, anti-
HCV, both HBsAg and anti-HCV, and neither were 58
(IQR, 35–92), 40 (IQR, 30–75), 59 (IQR, 36–105), and
58 (IQR, 40–101) units/L, respectively. The median ALT
among patients reactive to HBsAg, anti-HCV, both HBsAg
and anti-HCV, and neither were 33 (IQR, 22–54), 28
(IQR, 17–50), 37 (IQR, 20–63), and 37 (IQR, 24–52)
units/L, respectively. The median bilirubin level amongBMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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patients reactive to HBsAg, anti-HCV, both HBsAg and
anti-HCV, and neither were 0.6 (IQR, 0.4–1.1), 0.5 (IQR,
0.3–0.9), 0.6 (IQR, 0.4–1.3), and 0.7 (IQR, 0.5–1.1) mg/
dL, respectively. Of the 759 with available liver function
test results, elevated levels were found in 18/70 (26%)
patients with HBsAg (p = 0.02 compared to non-reactive),
37/236 (16%) patients with HCV (p = 0.93 compared to
non-reactive), 6/27 (22%) patients with both (p = 0.42
Enrollment of HIV-infected TB patients in the study Figure 1
Enrollment of HIV-infected TB patients in the study.BMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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Table 1: Characteristics and clinical features of HIV-infected TB patients at the time of TB diagnosis, stratified by markers for viral 
hepatitis infection.
Characteristics and clinical 
features
All patients  Non-reactive for HBsAg 
and anti-HCV
Reactive for Unknown
(n = 769) (n = 472) (n = 17)
Only HBsAg Only anti-HCV  HBsAg and anti-HCV 
(n = 43) (n = 210) (n = 27)
Characteristics
Age >34 years old 380 (49) 221 (47) 21 (49) 115 (55) 12 (44) 11 (65)
Male 538 (70) 294 (62) 32 (74) 175 (83) 25 (93) 12 (71)
>6th grade education 300 (39) 182 (39) 20 (47) 83 (40) 9 (33) 6 (35)
Employed 452 (59) 298 (63) 28 (65) 103 (49) 16 (59) 7 (41)
Single 237 (31) 125 (27) 14 (33) 83 (40) 10 (37) 5 (29)
Body mass index <18.5 443 (58) 270 (57) 24 (56) 116 (55) 21 (78) 12 (71)
Low TB knowledge 592 (77) 369 (78) 27 (63) 162 (77) 21 (78) 13 (77)
High TB stigma 500 (65) 294 (62) 26 (61) 146 (70) 20 (74) 14 (82)
Live in Bangkok 177 (23) 37 (8) 4 (9) 122 (58) 13 (48) 1 (6)
TB disease classification
Pulmonary TB 461 (60) 261 (55) 21 (49) 146 (70) 21 (78) 12 (71)
Smear positive 283 (37) 169 (36) 13 (62) 80 (38) 11 (52) 10 (59)
Abnormal chest x-ray 415 (54) 233 (49) 17 (81) 134 (64) 20 (95) 11 (65)
Extra-pulmonary TB 230 (30) 168 (36) 16 (37) 37 (18) 5 (19) 4 (24)
Pulmonary and extra-
pulmonary TB
78 (10) 43 (9) 6 (14) 27 (13) 1 (4) 1 (6)
TB treatment
Registered for TB treatment 
as new case
667 (87) 424 (90) 35 (81) 173 (82) 19 (70) 16 (94)
Received standard or 
extended HRZE
665 (87) 430 (91) 35 (81) 168 (80) 17 (63) 15 (88)
DOT by healthcare worker 
or village health volunteer
246 (32) 100 (21) 17 (40) 107 (51) 14 (52) 8 (47)
Drug and alcohol use, and 
incarceration history
Currently smoke 205 (27) 94 (20) 10 (23) 86 (41) 10 (37) 5 (29)
History of alcohol use 538 (70) 317 (67) 30 (70) 159 (76) 20 (74) 12 (71)
History of methamphetamine 
use
304 (40) 146 (31) 11 (26) 128 (61) 15 (56) 4 (24)
History of marijuana use 267 (35) 118 (25) 11 (26) 120 (57) 13 (48) 5 (29)
History of ketamine use 26 (3) 11 (2) 1 (2) 11 (5) 1 (4) 2 (12)
History of ecstasy use 32 (4) 16 (3) 1 (2) 12 (6) 1 (4) 2 (12)
History of sleeping pill use 138 (18) 56 (12) 9 (21) 64 (31) 7 (26) 2 (12)
History of inhalant use 130 (17) 53 (11) 8 (19) 57 (27) 9 (33) 3 (18)
History of injection drug use 199 (26) 43 (9) 4 (9) 134 (64) 15 (56) 3 (18)
History of incarceration 303 (39) 122 (26) 17 (40) 144 (69) 16 (59) 4 (24)
High-risk sexual practices
Have >4 sex partners in past 
6 months
9 (1) 5 (1) 1 (2) 2 (1) 1 (4) 0 (0)
Not always use condom* 247 (74) 151 (73) 13 (59) 67 (77) 6 (67) 10 (100)
Have sex with a sex worker 
in past 6 months*
29 (4) 17 (4) 3 (7) 7 (4) 2 (7) 0 (0)
Men who have sex with men 42 (8) 25 (9) 7 (22) 6 (4) 2 (8) 2 (17)
Laboratory studies
Aspartate aminotransferase ≥ 
120 units/L
67 (9) 35 (7) 7 (16) 18 (9) 4 (15) 3 (18)
Alanine aminotransferast ≥ 
165 units/L
17 (2) 10 (2) 2 (5) 3 (1) 1 (4) 1 (6)
Bilirubin >2 mg/dL 77 (10) 50 (11) 6 (14) 14 (7) 4 (15) 3 (18)
CD4+ T-lymphocyte* (cells/
μL), median (range)
63 (0–93) 53 (0–750) 41 (1–675) 76 (0–823) 101 (1–893) 139 (18–552)
Medicines taken during 
TB treatment
Co-trimoxazole 665 (87) 411 (87) 39 (91) 181 (86) 22 (82) 12 (71)BMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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compared to non-reactive), and 69/465 (15%) patients
that were non-reactive.
Risk factors for HBsAg and/or anti-HCV reactivity
Factors independently associated with HBsAg reactivity
included being a man who had sex with men (adjusted
odds ratio [AOR], 2.1; 95% confidence interval [CI], 1.1–
4.3) and having low TB knowledge (AOR, 1.8; 95% CI,
1.0–3.0; Table 2.1). Factors independently associated
with anti-HCV reactivity were being unemployed (AOR,
1.7; 95% CI, 1.1–2.5), having high TB stigma (AOR, 1.7;
95% CI, 1.0–2.7), currently smoking (AOR, 1.7; 95% CI,
1.0–2.9), having injection drug use history (AOR, 12.8;
95% CI, 7.0–23.2), and living in Bangkok (AOR, 15.8;
95% CI, 9.4–26.5; Table 2.2). Two factors were independ-
ently associated with having both HBsAg and anti-HCV
reactivity: having injection drug use history (AOR, 3.2;
95% CI, 1.0–9.8) and living in Bangkok (AOR, 2.7; 95%
CI, 1.1–6.6; Table 2.3).
TB treatment and outcomes
A standard first-line TB regimen (two months of isoniazid,
rifampin, pyrazinamide, and ethambutol followed by at
least four months of isoniazid and rifampin) was used in
665 (87%) patients. Co-trimoxazole, fluconazole, and
anti-retroviral therapy (ART) were taken by 665 (86%),
454 (59%), and 328 (43%), respectively, during TB treat-
ment. The total follow-up time was 428 person-years.
Four hundred and ninety-three patients (64%) were suc-
cessfully treated (Table 3). Of the remaining patients, 6
(1%) failed treatment, 130 (17%) died, 65 (9%)
defaulted, 70 (9%) transferred out, and 5 (1%) were still
on treatment at the time follow-up ended.
At least one adverse event occurred in 236 (31%) patients.
The most common adverse events occurring during TB
treatment (Table 3) were rash (15%), followed by
immune reconstitution inflammatory syndrome (7%),
liver disease (5%), diarrhea (5%), pneumonia (4%), men-
ingitis (3%), HIV wasting syndrome (3%), cryptococcosis
(2%), herpes zoster (2%), and recurrent upper respiratory
infections or sinusitis (1%).
Impact of viral hepatitis on adverse events and treatment 
outcomes
HIV wasting syndrome and upper respiratory infections or
sinusitis occurring during TB treatment were the only
health conditions significantly associated with markers of
viral hepatitis infection (p = 0.02 and p = 0.05, respec-
tively). Upper respiratory infections or sinusitis was
reported by 7% of patients reactive to HBsAg and anti-
HCV, 1% of patients non-reactive to any viral markers,
and none in other groups. HIV wasting syndrome was
reported in nearly 12% of patients with missing viral hep-
atitis markers, but in 4% of all other groups.
We analyzed the odds of death compared with successful
TB treatment, stratified by markers of viral hepatitis infec-
tion and adjusted for factors known to be associated with
TB treatment outcome. There was no difference in the
odds of death for patients HBsAg reactive, anti-HCV reac-
tive, or HBsAg and anti-HCV reactive, compared with
patients non-reactive to any viral marker (Table 4.1). The
findings were not significantly different when we ana-
lyzed all TB patients and only culture-confirmed patients.
Factors adjusted for in this analysis included TB disease
severity, HIV disease severity (i.e., CD4 count at time of
enrollment), co-trimoxazole use, fluconazole use, anti-
retroviral use, directly observed therapy use, hospitaliza-
tion at enrollment, and previous TB treatment.
We analyzed the odds of either death or default compared
with successful TB treatment, stratified by viral hepatitis
markers and adjusted for factors known to be associated
with TB treatment outcome as noted above. Among
patients HBsAg reactive, the odds of death or default was
2.7 (95% CI, 1.1–6.4) compared with patients non-reac-
tive to any viral marker. This difference was also seen in
the subset of culture-confirmed TB patients (Table 4.2).
The odds of death or default was also increased in patients
anti-HCV reactive, but this was only found in the subset of
patients with culture-confirmed TB. Adjusting for injec-
tion drug use did not change the findings from these anal-
yses.
Discussion
Among HIV-infected TB patients living in Thailand, mark-
ers of viral hepatitis infection, particularly hepatitis C
virus, were common and strongly associated with known
behavioral risk factors. Viral hepatitis markers were not
strongly associated with death or the development of clin-
ical hepatitis during TB treatment.
The rate of HBsAg seropositivity in HIV-infected TB
patients was similar to that found in the general Thai pop-
ulation.[15] In future years, the rate of HBV infection is
Fluconazole 454 (59) 309 (66) 27 (63) 100 (48) 11 (41) 7 (41)
Anti-retroviral therapy 328 (43) 247 (52) 25 (58) 48 (23) 5 (19) 3 (18)
TB, tuberculosis; HIV, human immunodeficiency virus; HRZE, isoniazid, rifampin, pyrazinamide, ethambutol; DOT, directly observed therapy; 
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus
*Among those with available data/results
Table 1: Characteristics and clinical features of HIV-infected TB patients at the time of TB diagnosis, stratified by markers for viral 
hepatitis infection. (Continued)BMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
Page 7 of 10
(page number not for citation purposes)
likely to decline considerably, because universal hepatitis
B childhood vaccination was integrated into the national
expanded program on immunization in 1992.[16]
Among HIV-infected TB patients, the strongest association
with HBV infection was being a man having sex with men.
In contrast to previous studies, we did not find an associ-
ation between high-risk sexual practices (e.g., not using a
condom, multiple partners) and HBsAg seropositivity,
possibly because our sexual history questions probed only
recent behavior and patients were generally quite
Table 2: Univariate and multivariate logistic regression analyses of risk factors for viral hepatitis infections among HIV-infected TB 
patients.
1. Risk factors for HBsAg reactive (n = 732)
Risk factors OR 95% CI p AOR 95% CI p
LU LU
Male 2.0 1.1 3.7 0.03 1.6 0.8 3.1 0.16
Man having sex with men 2.3 1.2 4.6 0.02 2.1 1.1 4.3 0.04
Low TB knowledge 1.6 0.9 2.8 0.08 1.8 1.0 3.0 0.04
History of inhalant use 1.7 0.9 3.0 0.08 1.4 0.7 2.7 0.29
History of incarceration (jail) 1.4 0.9 2.3 0.20 1.2 0.7 2.0 0.62
Had >4 sex partners in past 6 months 2.8 0.6 13.9 0.20 1.9 0.4 9.4 0.46
2. Risk factors for anti-HCV reactive (n = 736)
Risk factors OR 95% CI P AOR 95% CI p
LU LU
Male 3.1 2.1 4.7 <0.01 1.4 0.8 2.5 0.25
Age >34 years 1.3 1.0 1.8 0.09 1.2 0.8 2.0 0.37
Unemployed 1.7 1.3 2.5 <0.01 1.7 1.1 2.5 0.03
High TB stigma 1.4 1.0 2.0 0.04 1.7 1.0 2.7 0.04
Currently smoke 2.7 1.9 3.8 <0.01 1.7 1.0 2.9 0.04
History of alcohol use 1.5 1.1 2.1 0.03 1.0 0.6 1.7 0.92
History of methamphetamine use 3.6 2.6 5.0 <0.01 0.7 0.4 1.3 0.32
History of marijuana use 3.9 2.8 5.5 <0.01 1.4 0.8 2.5 0.30
History of ketamine use 2.3 1.0 5.1 0.05 0.9 0.2 4.2 0.86
History of ecstasy use 1.7 0.8 3.6 0.15 1.1 0.3 4.9 0.88
History of sleeping pill use 3.0 2.1 4.4 <0.01 1.1 0.6 2.0 0.84
History of inhalant use 2.9 2.0 4.3 <0.01 0.9 0.5 1.7 0.68
History of injection drug use 17.2 11.5 25.6 <0.01 12.8 7.0 23.2 <0.01
History of incarceration (jail) 5.6 4.0 7.8 <0.01 1.3 0.8 2.3 0.35
Live in Bangkok 15.3 10.2 23.1 <0.01 15.8 9.4 26.5 <0.01
3. Risk factors for HBsAg and anti-HCV reactive (n = 740)
Risk factors OR 95% CI P AOR 95% CI p
LU LU
Male 5.6 1.3 23.8 0.02 3.2 0.7 14.4 0.14
History of methamphetamine use 2.1 0.9 4.6 0.07 0.7 0.2 2.2 0.54
History of marijuana use 1.9 0.9 4.2 0.11 0.8 0.3 2.4 0.69
History of inhalant use 2.7 1.2 6.2 0.02 1.9 0.7 5.4 0.21
History of injection drug use 4.5 2.0 10.2 <0.01 3.2 1.0 9.8 0.05
History of incarceration (jail) 2.3 1.0 4.9 0.04 1.0 0.3 3.3 0.97
Live in Bangkok 3.2 1.5 7.0 <0.01 2.7 1.1 6.6 0.03
TB, tuberculosis; HIV, human immunodeficiency virus; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; L, lower bound; U, upper 
bound; HBsAg, hepatitis B surface antigen; Variables for which p = 0.20 in univariate analyses were included in multivariate logistic regression 
analysisBMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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ill.[19,20] Men who have sex with men are at high risk of
HIV in Thailand, and the prevalence of HIV infection has
risen dramatically in recent years.[21] This population,
therefore, will increasingly require healthcare personnel
sufficiently trained and equipped to manage concomitant
HIV, TB, and viral hepatitis infection. We found that
HBsAg seropositive patients were more likely to have ele-
vated liver function enzymes, but, in contrast to studies in
other settings, we found that TB treatment was well-toler-
ated, with rates of acquired hepatitis and other adverse
events similar to patients not HBsAg seropositive.[22,23]
Rates of default, however, were higher in this population,
suggesting that further research is needed to explore
whether medication intolerance and occult hepatitis
could be factors leading to TB treatment default.
Antibodies to HCV were found in nearly one-third of
patients, and nearly two-thirds of these cases reported a
history of injection drug use. Other independent risk fac-
tors included living in Bangkok and smoking; given the
known association between HCV infection and injection
drug use[24], it is possible that living in Bangkok and
smoking were surrogate markers for patients that did not
accurately disclose their injection drug use history. We
found that TB patients with HCV and HIV infection had
adverse event rates and treatment outcomes no worse
than TB patients with only HIV infection. Further research
is needed to confirm this finding in other countries and in
populations whose HCV infection is better characterized
through measurement of HCV viral load, HCV genotype,
and pathological evidence of liver disease.
Table 3: Most common adverse events during TB treatment and treatment outcomes among HIV-infected TB patients, stratified by 
markers for viral hepatitis infections.
Adverse events 
and treatment 
outcomes
All patients 
(n = 769)
Non-reactive for 
HBsAg and anti-
HCV (n = 472)
Reactive for Unknown (n = 17)
Only HBsAg 
(n = 43)
Only anti-HCV 
(n = 210)
HBsAg and anti-
HCV (n = 27)
n (%) n (%) n (%) n (%) n (%) n (%)
Adverse events
Rash 116 (15) 69 (15) 7 (16) 32 (15) 4 (15) 4 (24)
Immune 
reconstitution 
inflammatory 
syndrome*
16 (7) 12 (7) 0 (0) 2 (6) 1 (13) 1 (100)
Liver disease 41 (5) 23 (5) 3 (7) 12 (6) 2 (7) 1 (6)
Diarrhea 36 (5) 22 (5) 2 (5) 7 (3) 2 (7) 3 (18)
Pneumonia 
including PCP
30 (4) 15 (3) 2 (5) 11 (5) 1 (4) 1 (6)
Meningitis 20 (3) 11 (2) 2 (5) 6 (3) 1 (4) 0 (0)
HIV wasting 
syndrome
19 (3) 15 (3) 0 (0) 1 (1) 1 (4) 2 (12)
Cryptococcosis 16 (2) 8 (2) 0 (0) 8 (4) 0 (0) 0 (0)
Herpes zoster 12 (2) 5 (1) 2 (5) 4 (2) 1 (4) 0 (0)
Recurrent upper 
respiratory 
infections or 
sinusitis
7 (1) 5 (1) 0 (0) 0 (0) 2 (7) 0 (0)
Treatment 
outcomes
Cure 210 (27) 133 (28) 7 (16) 63 (30) 6 (22) 1 (6)
Complete 283 (37) 190 (40) 16 (37) 65 (31) 9 (33) 3 (18)
Failure 6 (1) 3 (1) 1 (2) 2 (1) 0 (0) 0 (0)
Die 130 (17) 72 (15) 5 (12) 37 (18) 7 (26) 9 (53)
Default 65 (9) 34 (7) 8 (19) 20 (10) 1 (4) 2 (12)
Transfer out 70 (9) 37 (8) 5 (12) 22 (11) 4 (15) 2 (12)
On treatment 5 (1) 3 (1) 1 (2) 1 (1) 0 (0) 0 (0)
TB, tuberculosis; HIV, human immunodeficiency virus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PCP, pneumocystis carinii 
pneumonia.
*Among 237 patients eligible to be evaluated only.BMC Public Health 2008, 8:245 http://www.biomedcentral.com/1471-2458/8/245
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Our study is subject to important limitations. First, we
only performed limited laboratory testing on patients.
Confirmatory tests, other serological markers of viral hep-
atitis, and viral load levels were not performed. Only a
small proportion of those who become HBV infected will
remain HBsAg positive; thus, factors associated with
HBsAg positivity may be risk factors for HBV infection or
determinants of chronic HBV disease. Serologic testing
was also done in different laboratories using different
commercial assays. Second, patients were only required to
have liver function tests measured at the beginning of
treatment. Our estimates of acquired hepatitis were based
on persons who remained on TB treatment, had symp-
toms, sought care, and had a clinician diagnose clinical
hepatitis. The incidence of clinical hepatitis developing
during TB treatment, therefore, could be substantially
higher than what we have reported, given the large
number of patients that defaulted, transferred out, and
died during treatment. The same limitation applies to our
ascertainment of all adverse events. Finally, our sample
size of patients may have been too small to detect low lev-
els of hepatotoxicity, and the population we studied may
not be representative of all HIV-infected TB patients in
Thailand.
Conclusion
The global burden of TB has risen dramatically in the past
ten years due to the HIV epidemic. While HCV rates have
similarly increased, the impact of viral hepatitis on the TB/
HIV syndemic is less clear. This study provides important
insight into the burden of viral hepatitis infection among
HIV-infected TB patients living in Thailand, and demon-
strates the need for further epidemiologic and clinical
studies to optimize the management of this complicated
medical condition.
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